Evidence map›Paper›PMID 28928126›Full record

ReviewBlood2017

Chimeric antigen receptor T-cell therapies for multiple myeloma.

Lekha Mikkilineni, James N Kochenderfer

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03778346 (Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells), which is not on this map. Cited by 145 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed, 7 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03778346 phase1unknown statusnot on this mapstarted 2018, after this paper: background citation

Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells

TypeinterventionalSponsorThe Sixth Affiliated Hospital of Wenzhou Medical UniversityRan2018 to 2022Enrolled30ConditionsRRMMArmsCAR-T therapy in Relapsed/Refractory multiple myeloma
3 · Its place in the literature

Who cites it

145 citing papers in PubMed, 7 syntheses or guidelines pooled it, 215 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Immune Cell Homing Hydrogels for Cancer Immunotherapy.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  19. Review
  20. Review

85 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Lekha MikkilineniMedical Oncology Fellowship Program and.
James N KochenderferExperimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD.
National Cancer Institute · US

Funding

Development of Chimeric Antigen Receptors Targeting Multiple MyelomaZIABC011439 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOCHENDERFER, JAMES · 2012 to 2025
$9.5M
6 · The paper itself

Abstract

Multiple myeloma (MM) is a nearly always incurable malignancy of plasma cells, so new approaches to treatment are needed. T-cell therapies are a promising approach for treating MM, with a mechanism of action different than those of standard MM treatments. Chimeric antigen receptors (CARs) are fusion proteins incorporating antigen-recognition domains and T-cell signaling domains. T cells genetically engineered to express CARs can specifically recognize antigens. Success of CAR-T cells (CAR-Ts) against leukemia and lymphoma has encouraged development of CAR-T therapies for MM. Target antigens for CARs must be expressed on malignant cells, but expression on normal cells must be absent or limited. B-cell maturation antigen is expressed by normal and malignant plasma cells. CAR-Ts targeting B-cell maturation antigen have demonstrated significant antimyeloma activity in early clinical trials. Toxicities in these trials, including cytokine release syndrome, have been similar to toxicities observed in CAR-T trials for leukemia. Targeting postulated CD19

Indexed as

Antigens, CD19HumansImmunotherapy, AdoptiveMultiple MyelomaNeoplastic Stem CellsPlasma CellsReceptors, Antigen, T-CellRecombinant Fusion ProteinsT-LymphocytesAntigens, CD19Receptors, Antigen, T-CellRecombinant Fusion Proteins

Identifiers

PMID28928126
PMCPMC5731088
OpenAlexW2755114342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.